Series A · AI & Machine Learning · Berlin, Germany · Founded 2023 · 18–18 employees
StratifAI is a precision oncology startup developing AI-powered biomarkers through its Polaris platform to improve cancer diagnosis and treatment decisions. The company uses multimodal AI to analyze routine histology images and clinical data to predict cancer recurrence risk and identify drug responders. Founded in 2023 by renowned researchers who have published over 100 articles in top-tier journals, StratifAI has raised $16.3M in funding and is advancing regulatory approvals for its first product, Polaris Breast, which assesses metastatic risk in early breast cancer. The company collaborates with leading oncology institutions and pharmaceutical companies to generate clinical evidence for real-world adoption.